Feeds:
Posts
Comments

Archive for the ‘Precision Cancer Medicine’ Category

Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter

Posted in Alzheimer's Disease, Amino acids, Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence Applications in Health Care, Artificial Intelligence in Health Care - Tools & Innovations, Artificial Intelligence in Medicine - Application for Diagnosis, Artificial Intelligence in Medicine - Applications in Therapeutics, Autophagosome, Big Data, Bio Instrumentation in Experimental Life Sciences Research, Biochemical pathways, Ca2+ triggered activation, Ca2+ triggered activation, Calcium, Calcium Signaling, Calmodulin Kinase and Contraction, CANCER BIOLOGY & Innovations in Cancer Therapy, cancer metabolism, Cancer-Immune Interactions, Cell Biology, Signaling & Cell Circuits, Cell Processing System in Cell Therapy Process Development, cell-based therapy, Chemical Biology and its relations to Metabolic Disease, Circulating Tumor Cells (CTC), combination immunotherapies., CT, Deep Learning, Echocardiography, Engineering Better T Cells, Enzymes and isoenzymes, Epigenetics and Environmental Factors, Exosomes, Genome Biology, Genomic Expression, Genomic Testing: Methodology for Diagnosis, Immune Engineering, Immune Modulatory, Immunotherapy, Intelligent Information Systems, Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, Machine Learning, Mechanical Assist Devices: LVAD, RVAD, BiVAD, Artificial Heart, Medical Devices R&D Investment, Medical Imaging Technology, Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound, Metabolic Immuno-Oncology, Metabolism, Microbiome and Responses to Cancer Therapy, Modulating Macrophages in Cancer Immunotherapy, MRI, mRNA, mRNA Therapeutics, Natural Language Processing (NLP), Neurodegenerative Diseases, NK Cell-Based Cancer Immunotherapy, Noninvasive Diagnostic Fractional Flow Reserve (FFR) CT, Nutrition, Nutrition and Phytochemistry, Nutrition Disorders, Nutritional Supplements: Atherogenesis, lipid metabolism, Pancreatic cancer, Patient-centered Medicine, PCI, Peripheral Arterial Disease & Peripheral Vascular Surgery, Personalized and Precision Medicine & Genomic Research, Precision Cancer Medicine, Prostate Cancer: Monitoring vs Treatment, Proteins, Proteomics, Robotic-assisted percutaneous coronary intervention, Robotically assisted Cardiothoracic Surgery, stem cell biology and patient-specific, Surgical Procedure, Synthetic Immunology: Hacking Immune Cells, Transcatheter Aortic Valve Replacement via the Transcarotid Access, tumor microenvironment, Ubiquitin, Ultra Sound, Variation in human protein-coding regions on January 10, 2026| Leave a Comment »

Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter

Article selection: Aviva Lev-Ari, PhD, RN

 

#1 – February 20, 2016

Contributions to Personalized and Precision Medicine & Genomic Research

Author: Larry H. Bernstein, MD, FCAP

https://www.linkedin.com/pulse/contributions-personalized-precision-medicine-genomic-aviva/?trackingId=IXDBMmp4SR6vVYaXKPmfqQ%3D%3D

http://pharmaceuticalintelligence.com/contributors-biographies/members-of-the-board/larry-bernstein/

 

#2 – March 31, 2016

Nutrition: Articles of Note @PharmaceuticalIntelligence.com

Author and Curators: Larry H. Bernstein, MD, FCAP and Curator: Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/nutrition-articles-note-pharmaceuticalintelligencecom-aviva/?trackingId=IXDBMmp4SR6vVYaXKPmfqQ%3D%3D

 

#3 – March 31, 2016

Epigenetics, Environment and Cancer: Articles of Note @PharmaceuticalIntelligence.com

Author and Curators: Larry H. Bernstein, MD, FCAP and Curator: Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/epigenetics-environment-cancer-articles-note-aviva-lev-ari-phd-rn/?trackingId=IXDBMmp4SR6vVYaXKPmfqQ%3D%3D

 

#4 – April 5, 2016

Alzheimer’s Disease: Novel Therapeutical Approaches — Articles of Note @PharmaceuticalIntelligence.com

Curators: Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/alzheimers-disease-novel-therapeutical-approaches-lev-ari-phd-rn/?trackingId=IXDBMmp4SR6vVYaXKPmfqQ%3D%3D

http://pharmaceuticalintelligence.com/2016/04/05/alzheimers-disease-novel-therapeutical-approaches-articles-of-note-pharmaceuticalintelligence-com/

 

#5 – April 5, 2016

Prostate Cancer: Diagnosis and Novel Treatment – Articles of Note  @PharmaceuticalIntelligence.com

Curators: Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/prostate-cancer-diagnosis-novel-treatment-articles-lev-ari-phd-rn/?trackingId=IXDBMmp4SR6vVYaXKPmfqQ%3D%3D

http://pharmaceuticalintelligence.com/2016/04/05/prostate-cancer-diagnosis-and-novel-treatment-articles-of-note-pharmaceuticalintelligence-com/ 

 

#6 – May 1, 2016

Immune System Stimulants: Articles of Note @pharmaceuticalintelligence.com

Curators: Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/immune-system-stimulants-articles-note-aviva-lev-ari-phd-rn/?trackingId=IXDBMmp4SR6vVYaXKPmfqQ%3D%3D

 

#7 – May 26, 2016

Pancreatic Cancer: Articles of Note @PharmaceuticalIntelligence.com

Curator: Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/pancreatic-cancer-articles-note-aviva-lev-ari-phd-rn/?trackingId=0AT4eUwMQZiEXyEOqo58Ng%3D%3D

 

#8 – August 23, 2017

Proteomics, Metabolomics, Signaling Pathways, and Cell Regulation – Articles of Note, LPBI Group’s Scientists @ http://pharmaceuticalintelligence.com

Curators: Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/proteomics-metabolomics-signaling-pathways-cell-lev-ari-phd-rn/?trackingId=0AT4eUwMQZiEXyEOqo58Ng%3D%3D

 

#9 – August 17, 2017

Articles of Note on Signaling and Metabolic Pathways published by the Team of LPBI Group in @pharmaceuticalintelligence.com

Curator: Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/articles-note-signaling-metabolic-pathways-published-aviva/?trackingId=0AT4eUwMQZiEXyEOqo58Ng%3D%3D

 

#10 – October 8, 2017

What do we know on Exosomes?

Curator: Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/what-do-we-know-exosomes-aviva-lev-ari-phd-rn/?trackingId=0AT4eUwMQZiEXyEOqo58Ng%3D%3D

 

#11 – September 1, 2017

Articles on Minimally Invasive Surgery (MIS) in Cardiovascular Diseases by the Team @Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Curator: Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/articles-minimally-invasive-surgery-mis-diseases-team-aviva/?trackingId=CPyrP0SNQq2X9N4pSubFxQ%3D%3D

 

#12 – August 13, 2018

MedTech & Medical Devices for Cardiovascular Repair – Contributions by LPBI Team to Cardiac Imaging, Cardiothoracic Surgical Procedures and PCI

Curator: Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/medtech-medical-devices-cardiovascular-repair-lpbi-lev-ari-phd-rn/?trackingId=5EFVlg%2BQRLO5i%2FfGBEN2FQ%3D%3D

 

#13 – May 24, 2019

Resources on Artificial Intelligence in Health Care and in Medicine: Articles of Note at PharmaceuticalIntelligence.com @AVIVA1950 @pharma_BI

Curator: Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/resources-artificial-intelligence-health-care-note-lev-ari-phd-rn/?trackingId=5EFVlg%2BQRLO5i%2FfGBEN2FQ%3D%3D

 

#14 – December 19, 2025

AI in Health: The Voice of Aviva Lev-Ari, PhD, RN

Curator: Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/ai-health-voice-aviva-lev-ari-phd-rn-aviva-lev-ari-phd-rn-xgqie/?trackingId=5EFVlg%2BQRLO5i%2FfGBEN2FQ%3D%3D

 

#15 – January 7, 2026

NEW Foundation Multimodal Model in Healthcare: LPBI Group’s Domain-aware Corpus for 2025 Grok 4.1 Causal Reasoning & Novel Biomedical Relationships

Aviva Lev-Ari, PhD, RN, Founder of LPBI Group

https://www.linkedin.com/pulse/new-foundation-multimodal-model-healthcare-lpbi-2025-aviva-40h1e/?trackingId=5EFVlg%2BQRLO5i%2FfGBEN2FQ%3D%3D

Read Full Post »

Real Time Conferecence Coverage: Advancing Precision Medicine Conference Philadelphia PA November 1,2 2024  Deliverables

Posted in Artificial Intelligence Applications in Health Care, Big Data, Bio Instrumentation in Experimental Life Sciences Research, Cancer Genomics, Cancer-Immune Interactions, Circulating Tumor Cells (CTC), Conference Coverage with Social Media, Deep Learning, Immuno-Oncology & Genomics, Machine Learning, Personalized and Precision Medicine & Genomic Research, Pharmacogenomics, Precision Cancer Medicine, Proteomics, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Scientific & Biotech Conferences: Press Coverage, Transcriptomics, Uncategorized, tagged , , , , , , , , , on October 21, 2025| 1 Comment »

Real Time Conferecence Coverage: Advancing Precision Medicine Conference Philadelphia PA November 1,2 2024  Deliverables

Curator: Stephen J. Williams, Ph.D.

Below are deliverables in form of real Time conference coverage from the Advancing Precision Medicine Confererence held this year in Philadelphia, PA.  The meeting brought together scientists and clinicians to discuss the challenges faced in implementing genomics and proteomics into precision medicine decision making workflow.  As summarized by a future release at the 2025 ASCO, there are many issues and hindrances to incorporating data obtained from sequencing to make a personalized medicine strategy.  The meeting focused on two main disease states: oncology and cardiovascular however most of  the live meeting notes are from the oncology tract.  In general it was discussed there are three areas which need to be addressed to correctly and more frequently incorporate precision medicine and genomic panel testing into clinical decision making workflow:

  1.  access to testing panels and testing methodology for both doctors and patients
  2. expert interpretation of results including algorithms needed to analyze the data
  3. more education of molecular biology and omics data and methodology in medical school to address knowledge gaps between clinicians and scientists

The issues can be summarized by a JCO report to ASCO in 2022:

 Helen Sadik, PhD, Daryl Pritchard, PhD https://orcid.org/0000-0003-2675-0371 dpritchard@personalizedmedicinecoalition.org, Derry-Mae Keeling, BSc, Frank Policht, PhD, Peter Riccelli, PhD, Gretta Stone, BS, Kira Finkel, MSPH, Jeff Schreier, MBA, and Susanne Munksted, MS.  Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non–Small-Cell Lung Cancer. 2022: JCO Precision Oncology; Volume 6. https://doi.org/10.1200/PO.22.00246

Personalized medicine presents new opportunities for patients with cancer. However, many patients do not receive the most effective personalized treatments because of challenges associated with integrating predictive biomarker testing into clinical care. Patients are lost at various steps along the precision oncology pathway because of operational inefficiencies, limited understanding of biomarker strategies, inappropriate testing result usage, and access barriers. We examine the impact of various clinical practice gaps associated with diagnostic testing-informed personalized medicine strategies on the treatment of advanced non–small-cell lung cancer (aNSCLC).

The authors used a  Diaceutics’ Data Repository, a multisource database including commercial and Medicare claims and laboratory data from over 500,000 patients with non–small-cell lung cancer in the United States. They  analyzed the number of patients with newly diagnosed aNSCLC who could have, but did not, benefit from a personalized treatment. The analysis was focused on identifying the gaps and at which steps during care did gaps existed which precipitated either lack of use of precision medicine testing or incorrect interpretation of results.

Their conclusions were alarming:

Most patients with aNSCLC eligible for precision oncology treatments do not benefit from them because of clinical practice gaps. This finding is likely reflective of similar gaps in other cancer types. An increased understanding of the impact of each practice gap can inform strategies to improve the delivery of precision oncology, helping to fully realize the promise of personalized medicine.

The links to the live meeting notes are given below and collection of tweets follow (please note this meeting did not have a Twitter hashtag)

Real Time Coverage Advancing Precision Medicine Annual Conference, Philadelphia PA November 1,2 2024

https://pharmaceuticalintelligence.com/2024/11/01/real-time-coverage-advancing-precision-medicine-annual-conference-philadelphia-pa-november-12-2024/

Real Time Coverage Morning Session on Precision Oncology: Advancing Precision Medicine Annual Conference, Philadelphia PA November 1 2024

https://pharmaceuticalintelligence.com/2024/11/01/real-time-coverage-morning-session-on-precision-oncology-advancing-precision-medicine-annual-conference-philadelphia-pa-november-1-2024/

Real Time Coverage Afternoon Session on Precision Oncology: Advancing Precision Medicine Annual Conference, Philadelphia PA November 1 2024

https://pharmaceuticalintelligence.com/2024/11/01/real-time-coverage-afternoon-session-on-precision-oncology-advancing-precision-medicine-annual-conference-philadelphia-pa-november-1-2024/ 

Real Time Coverage Morning Session on Precision Oncology: Advancing Precision Medicine Annual Conference, Philadelphia PA November 2 2024

https://pharmaceuticalintelligence.com/2024/11/04/real-time-coverage-morning-session-on-precision-oncology-advancing-precision-medicine-annual-conference-philadelphia-pa-november-2-2024/ 

Tweet Collection

Tweet Collection Advancing Precision Medicine Conference November 1,2 2024 Philadelphia PA

 

Read Full Post »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session October 4 2025

Posted in Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence Applications in Health Care, Artificial Intelligence in CANCER, Artificial Intelligence in Medicine - Application for Diagnosis, Artificial Intelligence in Medicine - Applications in Therapeutics, Bio-Ethics, BioBanking, BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Biological Networks, Biological Networks, Gene Regulation and Evolution, Cancer Genomics, Cancer Informatics, Clinical Diagnostics, Foundations for supporting Science and Education, Gene Regulation, Health Care System by Country, India, Intelligent Information Systems, Machine Learning, Natural Language Processing (NLP), Personalized and Precision Medicine & Genomic Research, Personalized Medicine Coalition, Precision Cancer Medicine, Proteomics, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Scientific & Biotech Conferences: Press Coverage, tumor microenvironment, tagged , , , , , , , , , , , , , , , , , , , , , on October 4, 2025| Leave a Comment »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session  October 4 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

1:40 – 2:30

AI in Precision Medicine

Dr. Ganhui Lan

Dr. Ganhui Lan VP, Data Science & Machine Learning, Genentech

Dr. Xiaoyan Wang

Dr. Xiaoyan Wang Research Professor, Department of Health Policy and Management, Tulane University Chief Scientist, SVP, Intelligent Medical Objects

Dr. Ahmad P. Tafti

Dr. Ahmad P. Tafti Assistant Professor, School of Computing and Information,School of Health and Rehabilitation Sciences, University of Pittsburgh Interim Director, Division of Scientific Affairs, Computational Pathology AI Center of Excellence

Jen Gilburg

Jen Gilburg (moderator)Deputy Secretary of Technology and Entrepreneurship, Dept. of Community and Economic Development, Commonwealth of Pennsylvania

  • AI will help reduce time for drug development especially in early phase of discovery but eventually help in all phases
  • Ganhui: for drug regulators might be more amenable to AI in clinical trials; AI may be used differently by clinicians
  • nonprofit in Philadelphia using AI to repurpose drugs (this site has posted on this and article will be included here)
  • Ganhui: top challenge of AI in Pharma; rapid evolution of AI and have to have core understanding of your needs and dependencies; realistic view of what can be done; AI has to have iterative learning; also huge vertical challenge meaning how can we allign the use of AI through the healthcare vertical layer chain like clinicians, payers, etc.
  • Ganhui sees a challenge for health companies to understand how to use AI in business to technology; AI in AI companies is different need than AI in healthcare companies
  • 95% of AI projects not successful because most projects are very discrete use

2:00-2:20

Building Precision Oncology Infrastructure in Low- and Middle-Income Countries

Razelle Kurzrock, MD

Sewanti Limaye, MD, Director, Medical & Precision Oncology; Director Clinical and Translational Oncology Research, Sir HN Reliance Foundation Hospital & Research Centre, Mumbai, India; Founder, Nova Precision AI; Co-Founder, Iylon Precision Oncology; Co-Chair, Asia Pacific Coalition Against Lung Cancer; Co-Chair,  Asia Pacific Immuno-Oncology; Member,  WIN Consortium

  • globally 60 precision initiatives but there really are because many in small countries
  • three out of five individuals in India die of cancer
  • precision medicine is a must and a hub and spoke model is needed in these places; Italy does this hub and spoke; spokes you enable the small places and bring them into the network so they know how and have access to precision medicine
  • in low income countries the challenge starts with biopsy: then diagnosis and biomarker is issue; then treatment decision a problem as they may not have access to molecular tumor boards
  • prevention is always a difficult task in LMICs (low income)
  • you have ten times more patients in India than in US (triage can be insurmountable)
  • ICGA Foundation: Indian Cancer Genome Atlas
  • in India mutational frequencies vary with geographical borders like EGFR mutations or KRAS mutations
  • genomic landscape of ovarian cancer in India totally different than in TCGA data
  • even different pathways are altered in ovarian cancer seen in North America than in India
  • MAY mean that biomarker panels need to be adjusted based on countries used in
  • the molecular data has to be curated for the India cases to be submitted to a tumor board
  • twenty diagnostic tests in market like TruCheck for Indian market; uses liquid biopsy
  • they are also tailoring diagnostic and treatment for India getting FDA fast track approvals

2:20-2:40

Co-targeting KIT/PDGRFA and Genomic Integrity in Gastrointestinal Stromal Tumors

Razelle Kurzrock, MD

Lori Rink, PhD, Associate Professor, Fox Chase Cancer Center

  • GIST are most common nesychymal tumor in GI tract
  • used to be misdiagnosed; was considered a leimyosarcoma
  • very asymptomatic tumors and not good prognosis
  • very refractory to genotoxic therapies
  • RTK KIT/PDGFRA gain of function mutations
  • Gleevec imatinib for unresectable GIST however vast majority of even responders become resistant to therapy and cancer returns
  • there is a mutation map for hotspot mutations and sensitivity for gleevec
  • however resistance emerged to ripretinib; in ATP binding pocket
  • over treatment get a polyclonal resistance
  • performed a kinome analysis; Wee1 looked like a potential target
  • mouse studies (80 day) showed good efficacy
  • avapiritinib ahs some neurotox and used in PDGFRA mut GIST model which is resistant to imitinib
  • but if use Wee1 inhibitor with TKI can lower dose of avapiritinib
  • cotargeting KIT/PDGFRA and WEE1 increases replicative stress
  • they are using PDX models to test these combinations
  • combination creates genomic instability

 

Read Full Post »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Late Morning Session Track 1 October 4 2025

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Genomics, Clinical & Translational, Clinical Diagnostics, Clinical Genomics, Conference Coverage with Social Media, FDA Regulatory Affairs, Genomic Expression, Genomic Testing: Methodology for Diagnosis, Healthcare costs and reimbursement, KRAS Mutation, Methylation, Personalized and Precision Medicine & Genomic Research, Precision Cancer Medicine, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, TP53 - Germline mutations, tagged , , , , , , , , , , , on October 4, 2025| Leave a Comment »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Late Morning Session Track 1 October 4 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

SESSION 3

Advances in Precision Oncology:
From Genomics to Targeted Therapies

11:10-11:55

Breaking the Glass Ceiling: Targeting KRAS in Pancreatic Cancer

Razelle Kurzrock, MD

Michael Pishvaian, MD, Associate Professor, Department of Oncology, Johns Hopkins University

Razelle Kurzrock, MD

Kim Reiss, MD, Associate Professor of Medicine (Hematology-Oncology), Hospital of the University of Pennsylvania

11:55-12:15

Charting the Future of Cancer Care: Precision Oncology and the Power of Genomics

Razelle Kurzrock, MD

Vivek Subbiah, MD,
Chief, Early-Phase Drug Development, Sarah Cannon Research Institute

12:15-12:35

Molecular Pathology as a Driver of Precision in Urological Cancers

Razelle Kurzrock, MD

Liang Cheng, MD, Professor and Vice Chair, Translational Research; Director of Anatomic and Molecular Pathology, Department of Pathology and Laboratory Medicine, Brown University Medical School, Lifespan Academic Medical Center

 

12:30-12:40

Non – CME – dSTRIDE™-HR: A Functional Biomarker for In Situ, ‘real-time’ Detection and Quantification of Homologous Recombination Activity.

Magda Kordon-Kiszala, PhD

Magda Kordon-Kiszala, PhD, CEO and co-founder, intoDNA

12:35-12:55

Epigenetic Plasticity and Tumor Evolution: Mechanisms of Resistance in Precision Oncology

Johnathan R. Whetstine, PhD

Johnathan R. Whetstine, PhD, Director, Cancer Epigenetics Institute, Director, Geonomics Resource, Fox Chase Cancer Center

  • Title: Epigenetic plasticity a gatekeeper to generating extrachromosomal DNA amplification and rearrangements
  • genetic events in cancer are actually controlled not random as he says
  • Fox Chase Cancer Center Epigenetics Institute; 5th year goal to understand epigenetic mechanisms to understand resistance and biomarker development; bring others and break down silos;  they are expanding and hiring and bringing into a network; March 5 2026 5th Annual Symposium Philadelphia Franklin Institute
  • DNA amplification is also chromosomal: integrated same locus or different regions or chromosomal duplication
  • KDM4A epigenetic demethylase controls transiet site specific DNA re-replication; can have focal control of DNA regions
  • you can control regional control of like EGFR amplification
  • can use Cy3 to find local regions
  • KDM3B inhibitor promotes transiet copy gains in KMT2A/MLL
  • EHMT2 is lysine demethylase is a driver of this copy amplification
  • this demethylase can change expression locally in one hour.. very fast
  • demethylases are very specific for their gene locus they control and so this demethylase only controls MLL gene
  • doxorubicin topoisomerase inhibitor can cause LOH in MLL locus and methylase inhibitor can reverse this
  • over twenty combinatorial regulators so this field is just budding

11:30-12:30

Companion Diagnostics in Hereditary and Chronic Diseases – Development, Regulatory Approval, and Commercialization – Non-CME Discussion

Huw Ricketts

Huw Ricketts PhD, Senior Director, CLIA Business Development, QIAGEN

Tricia Carrigan

Tricia Carrigan, PhD, BC Biosolutions

Arushi Agarwal

Arushi Agarwal, MS,  Partner, Health Advances

Melissa Reuter

Melissa Reuter, MS, MBA, Director, Precision Medicine Program Strategy, GSK

  • This is a session panel Discussion on the current state of companion diagnostic development, not just in oncology.  Regulatory aspects will be discussed
  • Arushi: There are alot of opportunities in non-oncology areas for companion diagnostics, and time to development may be an obstacle
  • Huw Rickets:  From a development standpoint most people are not looking at the diagnostic side but more on the therapeutic side.
  • Tricia:  There needs to be a shift in oncology drug development world, and pharma sees developing diagnostic is too expensive.
  • Meliisa: They try to engage early with the agencies to understand the regulatory landscape; GSK is very strong in their oncology platform but there are gaps in diagnostics and non-oncology programs
  • Arushi: seems in Pharma oncology and non-oncology programs seems siloed
  • for non-oncology many of the biomarkers may be rare… well under 25% of population
  • Huw: Qiagen trying to develop diagnostics for Parkinson’s but those rare genetic diseases are easier to develop
  • Arushi: neurodegenerative, NASH, and immuno diseases are big areas where companies are looking to make companion diagnostics
  • Huw: kidney  disease is a big focus to develop companion diagnostics for

 

12:30-12:40

Non – CME – dSTRIDE™-HR: A Functional Biomarker for In Situ, ‘real-time’ Detection and Quantification of Homologous Recombination Activity.

Magda Kordon-Kiszala, PhD

Magda Kordon-Kiszala, PhD, CEO and co-founder, intoDNA

Read Full Post »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session Track 1 October 3 2025

Posted in BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, BioTechnology - Venture Creation, Venture Capital, Cancer Informatics, Philanthropy to Academic Institution, Precision Cancer Medicine, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Scientific & Biotech Conferences: Press Coverage, Venture Capital, tagged , , , , , , , , , , , on October 3, 2025| 1 Comment »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session Track 1 October 3 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

WIN SYMPOSIUM

1:50-4:05

SESSION 4

From Targets to Trials:
Translating Discovery into Impact

1:50-2:10

Beyond Checkpoint Inhibitors: Targeted Immunotherapeutic Approaches for the Management of Solid Tumors

Andrea Ferreira-Gonzalez

Matthew Hadfield, DO, Assistant Professor of Medicine, Phase 1 Clinical Trials, Cutaneous Malignancies, The Warren Alpert Medical School of Brown University 

  • we need to turn these immuno-cold tumors into immuno ‘hot’ tumors so immunotherapy will be effective and recognize them
  • however each immunotherapies have their own toxicities
  • immunocheck points inhibitors: 50% of patients get very rough adverse events and have to stop therapy and give immunosuppressives
  • 60 yo female with urothelial carcinoma with chemo induced rash given pembrolizumab but got worse rash… had Steven Johnson Syndrome… fatal outcome from one cycle of PD-L1 inhibitor
  • so now we are giving these immune checkpoints earlier before even surgery… the overall survival better but there are certain personalized toxicities
  • up to 35% patients with cancer have chronic immuno related adverse events and dose limiting toxicities
  • 50% have low grade multiple toxicities (and they treat these AEs with steroids)
  • we have no biomarkers for these PD/PDL1 inhibitor adverse events

 

2:10-2:30

Implementing Molecular Profiling in Early Phase Clinical Trials: Precision from Bench to Bedside

Andrea Ferreira-Gonzalez

Apostolia M. Tsimberidou, MD, PhD, FASCO, FAAAS, Tenured Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer

  • power of biomarkers: BRCA2 null women with ovarian cancer success with olaparib even though at time was not approved except the biomarker known
  • every week they discuss with internal tumor board and consult with Foundation Medicine; however a mutational panel is great but need to understand the underlying effect on tumor biology
  • there are a handful of tumor agnostic targeted agents: based on biomarkers
  • she thinks digital twins will be helpful in determining cohort selection for clinical trails
  • she would like multiomics to be performed on every patient but how would this be done, especially in the ecosystem of the USA
  • from attendee question to speaker panel (from Indai): they have been running tmolecular boards but problem is when new targets or fusion proteins become known without a priori knowledge of them and no combination know what to do?

 

:30-2:40

Q&A

Andrea Ferreira-Gonzalez

Matthew Hadfield, DO, Assistant Professor of Medicine, Phase 1 Clinical Trials, Cutaneous Malignancies, The Warren Alpert Medical School of Brown University 

Andrea Ferreira-Gonzalez

Apostolia M. Tsimberidou, MD, PhD, FASCO, FAAAS, Tenured Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer

2:40-3:20

Non- CME Session: Venture Philanthropy

Andrea Ferreira-Gonzalez

Eric Heil, MBA, Managing Partner, Medical Excellence Capital

  • started a venture fund and then a 501(c) to give small grants
  • in venture philanthropy it is not traditional grant writing but more of a personal relationship; he says find other companies they have backed and ask them
  • all about networking
  • looked at 1400 deals but only invested in 13
  • back years ago his company biotech got ten million after 2009 from TAP but now it seems smaller bridge money
John Lehr, President & CEO, Parkinson's Foundation

John Lehr, President & CEO, Parkinson’s Foundation

  • runs venture philanthropy which is more like a mix of venture fund and granting agency
  • most run a for profit venture but mix model with 501c to fund small grants
Dr. Blaine Robinson

Dr. Blaine Robinson, PhD, Vice President of the Therapy Acceleration Program (TAP), Blood Cancer United

  • runs Blood Cancer United that offers grants for blood based research
  • they run three pillars: venture biotech funding, clinical trial funding, and academic research but most they take equity in biotechs
  • so venture philanthropy is more of equity investing and using those funds to fund younger companies like bridge between first round and series C
  • Blood Cancer United looking for million and above investment “first in class’; was early with Kite and UPenn (where are they now… are they still with them?)

3:20-4:10

eNSCLC Testing

Andrea Ferreira-Gonzalez

Kurt A. Schalper, MD, PhD, Associate Professor of Pathology and Medicine (Medical Oncology), Yale School of Medicine; Director Translational Immuno-Oncology Laboratory, Yale Cancer Center

  • lung cancer has seemed to be ahead with respect to biomarkers and precision therapies
  • at least with NCCN guidelines they are up to 14 therapeutic biomarkers not diagnostic biomarkers so very ahead on the clinical decision making on actionable mutations for lung cancer
  • so most of the testing is genomic mutational spectrum for oncogenic drivers
  • there are three protein based biomarkers: Met, PDL1,
  • FISH is still used for some fusions
  • NGS is more sensitive test but takes 2-4 weeks
  • the number of  detected EGFR variants are increasing so it is affecting the drug specificity
  • recently NRG1 fusions have been approved as a heregulin HER3 biomarker;
  • 15% which were detected as negative for fusions the patients actually responded because fusions were hard to detect; many false positives
  • 76% did not meet MET eligbility but only 13% were high enough for MET marker but was enough for FDA approval
  • some drugs beneficial for mutated version and some good for over expressed like MET or HER2 but where the mutation or exon skipping is important for therapy choice
  • we need better biobanking because we need more tissue; we loose more tissue during sectioning and not splitting blocks into two (one for diagnostic one for therapeutic)
  • liquid biopsy will find some mutations but other ones not very sensitivity in liquid biopsy like MET mutations (mutations may be assay specific)
  • some muts in bone marrow may just be in aging progenitor cells and sometimes in oncogene like BRAF but not cancer but dlonal homatopoesis (increased risk for myeloproliferative diseases but not solid tumors like melanoma)
  • clonal homatopoesis actually common so watch out when just relying on liquid biopsy

 

 

Read Full Post »

Conference Coverage 2025 Advancing Precision Medicine Conference, Philadelphia PA October 3-4 2025

Posted in Cancer Genomics, Cancer Informatics, Cardiovascular Pharmacogenomics, Circulating Tumor Cells (CTC), Clinical & Translational, Clinical Genomics, Conference Coverage with Social Media, Genomic Expression, Precision Cancer Medicine, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Scientific & Biotech Conferences: Press Coverage, tagged , , , , , , , , on October 2, 2025| 1 Comment »

Conference Coverage 2025 Advancing Precision Medicine Conference, Philadelphia PA October 3-4 2025

Reporter: Stephen J. Williams, PhD

The Annual Advanced Precision Medicine Conference will be held at the Pennsylvania Convention Center October 3-4 2025 in Philadelphia PA.   Advancing Precision Medicine is an organization dedicated to provide education and discourse among medical professionals to advance the field of precision therapeutics and diagnostics in cancer, cardiovascular, and other diseases.  The Annual symposium is held in Philadelphia.

The event will consist of two parallel tracks composed of keynote addresses, panel discussions and fireside chats which will encourage audience participation. Over the course of the two-day event leaders from industry, healthcare, regulatory bodies, academia and other pertinent stakeholders will share an intriguing and broad scope of content.

This event will consist of three immersive tracks, each crafted to explore the multifaceted dimensions of precision medicine. Delve into Precision Oncology, where groundbreaking advancements are reshaping the landscape of cancer diagnosis and treatment. Traverse the boundaries of Precision Medicine Outside of Oncology, as we probe into the intricate interplay of genetics, lifestyle, and environment across a spectrum of diseases and conditions including rare disease, cardiology, ophthalmology, and neurodegenerative disease. Immerse yourself in AI for Precision Medicine, where cutting-edge technologies are revolutionizing diagnostics, therapeutics, and patient care. Additionally, explore the emerging frontiers of Spatial Biology and Mult-Omics, where integrated approaches are unraveling the complexities of biological systems with unprecedented depth and precision.

https://www.advancingprecisionmedicine.com/ 

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

APM is a mission-driven team dedicated to advancing clinical practice through education in precision medicine, oncology, and pathology. Our expert-led programs bring together clinicians, pathologists, pharmacists, nurses, and researchers from across the country.

What We Offer

In 2025, we’re proud to offer three specialized event series—each tailored to a different corner of the healthcare ecosystem:

Register here for the 2025 Conference: https://www.advancingprecisionmedicine.com/apm-home/apm-annual-conference-and-exhibition-in-philadelphia/ 

Where discovery meets application – and science transforms lives.

What’s New in 2025?

Four Specialized Tracks:

Track 1 – 2025 WIN Symposium: Progress and Challenges in Precision Oncology
Presented in partnership with Advancing Precision Medicine

As the official 2025 WIN Symposium, this dedicated track will explore the evolving landscape of precision oncology, highlighting both groundbreaking advances and the ongoing challenges of translating molecular insights into clinical impact. Curated by the WIN Consortium, the program will feature global leaders in cancer research, diagnostics, and therapeutic innovation—offering a comprehensive view of how precision medicine is reshaping oncology across tumor types and care settings.

Track 2 – Day 1 – Multi-Omics Integration, Day 2 – Precision Medicine Outside of Oncology

From genomics and transcriptomics to proteomics and metabolomics—this track highlights how multi-layered data is revolutionizing systems biology and clinical decision-making.

Diving into applications across cardiovascular, neurology, rare disease, infectious disease, and other therapeutic areas where precision tools are reshaping clinical practice.

 

Why Attend?

  • Cutting-Edge Innovation: Explore AI-powered solutions, multi-omics workflows, clinical trial design, and real-world implementation.
  • Renowned Speakers: Hear from global thought leaders in translational research, biotech innovation, and personalized therapeutics.
  • Dynamic Format: Keynotes, fireside chats, panels, and audience-interactive discussions across four concurrent tracks.
  • Unmatched Networking: Collaborate with scientists, startups, executives, regulators, and investors shaping tomorrow’s care.
  • Philadelphia Advantage: Centrally located near premier academic institutions, hospitals, incubators, and venture capital networks.

Who Should Attend?

Researchers, clinicians, data scientists, regulatory experts, startup founders, investors, tech transfer professionals, and healthcare leaders.

Let’s advance a future that is more predictive, preventive, and precise—together.

Keynote Speaker

  • William Kaelin, Jr, MD

    2019 Nobel Laureate
    Sidney Farber Professor, Harvard Medical School and Dana-Farber Cancer Institute

2019 Nobel Laureate

Sidney Farber Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute 

Senior Physician-Scientist at Brigham and Women’s Hospital

Howard Hughes Medical Institute Investigator

William Kaelin is the Sidney Farber Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute, Senior Physician-Scientist at Brigham and Women’s Hospital and Howard Hughes Medical Institute Investigator. He obtained his undergraduate and M.D. degrees from Duke University and completed his training in Internal Medicine at the Johns Hopkins Hospital, where he served as chief medical resident. He was a clinical fellow in Medical Oncology at the Dana-Farber Cancer Institute and later a postdoctoral fellow in David Livingston’s laboratory, during which time he was a McDonnell Scholar.

A Nobel Laureate, Dr. Kaelin received the 2019 Nobel Prize in Physiology or Medicine. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the National Academy of Medicine, the American Society of Clinical Investigation, and the American College of Physicians. He previously served on the National Cancer Institute Board of Scientific Advisors, the AACR Board of Trustees, and the Institute of Medicine National Cancer Policy Board. He is a recipient of the Paul Marks Prize for cancer research from the Memorial Sloan-Kettering Cancer Center; the Richard and Hinda Rosenthal Prize from the AACR; the Doris Duke Distinguished Clinical Scientist award; the 2010 Canada International Gairdner Award; ASCI’s Stanley J. Korsmeyer Award; the Scientific Grand Prix of the Foundation Lefoulon-Delalande; the Wiley Prize in Biomedical Sciences; the Steven C. Beering Award; the AACR Princess Takamatsu Award; the ASCO Science of Oncology Award; the Helis Award; the Albert Lasker Basic Medical Research Prize; the Massry Prize; the Harriet P. Dustan Award for Science as Related to Medicine from the American College of Physicians.

Dr. Kaelin’s research seeks to understand how, mechanistically, mutations affecting tumor-suppressor genes cause cancer. His laboratory is currently focused on studies of the VHL, RB-1, and p53 tumor suppressor genes. His long-term goal is to lay the foundation for new anticancer therapies based on the biochemical functions of such proteins. His work on the VHL protein helped to motivate the eventual successful clinical testing of VEGF inhibitors for the treatment of kidney cancer. Moreover, this line of investigation led to new insights into how cells sense and respond to changes in oxygen, and thus has implications for diseases beyond cancer, such as anemia, myocardial infarction, and stroke. His group also showed that leukemic transformation by mutant IDH was reversible, setting the stage for the development and approval of mutant IDH inhibitors, and discovered how thalidomide-like drugs kill myeloma cells by degrading two otherwise undruggable transcription factors,

2025 Steering Committee
Wafik S. El-Deiry, MD, PhD, FACP

Chair
WIN Consortium

Kristine Ashcraft
Marni Falk, MD

Distinguished Endowed Chair, Department of Pediatrics
Executive Director, Mitochondrial Medicine Frontier Program
CHOP

Arutha Kulasinghe, PhD

Associate Professor, Frazer Institute, University of Queensland; Founding Scientific Director, Queensland Spatial Biology Centre

Adrian Lee
Adrian Lee, PhD

Professor and Director
Institute for Precision Medicine
University of Pittsburgh

Howard McLeod
Howard McLeod, PharmD

CHAIR

Professor & Center Director
Utah Tech University

Emanuel Petricoin, PhD

Co-Director Center, Applied Proteomics & Molecular Medicine
George Mason University

Jasmine Plummer
Jasmine Plummer

Founding Director, Center for Spatial Omics
Member, Comprehensive Cancer Center
St. Jude’s Children’s Research Hospital

Kristine Ashcraft
Giselle Sholler, MD

Director, Pediatric Oncology Research
Penn State Hershey Children’s Hospital

Wafik S. El-Deiry, MD, PhD, FACP

Chair
WIN Consortium

Kristine Ashcraft
Marni Falk, MD

Distinguished Endowed Chair, Department of Pediatrics
Executive Director, Mitochondrial Medicine Frontier Program
CHOP

Arutha Kulasinghe, PhD

Associate Professor, Frazer Institute, University of Queensland; Founding Scientific Director, Queensland Spatial Biology Centre

Adrian Lee
Adrian Lee, PhD

Professor and Director
Institute for Precision Medicine
University of Pittsburgh

Howard McLeod
Howard McLeod, PharmD

CHAIR

Professor & Center Director
Utah Tech University

Emanuel Petricoin, PhD

Co-Director Center, Applied Proteomics & Molecular Medicine
George Mason University

Jasmine Plummer
Jasmine Plummer

Founding Director, Center for Spatial Omics
Member, Comprehensive Cancer Center
St. Jude’s Children’s Research Hospital

Kristine Ashcraft
Giselle Sholler, MD

Director, Pediatric Oncology Research
Penn State Hershey Children’s Hospital

Presentations

A diverse group of more than 90 key opinion leaders will convene to explore the critical forces shaping the future of healthcare. Representing a range of disciplines—including genomics, bioinformatics, clinical research, biopharma, technology, and investment—these experts will lead discussions on the latest advancements and challenges in precision medicine.

Topics will include the evolution of genomic sequencing technologies, ethical considerations in managing patient data, the integration of AI in diagnostics, and strategies for translating innovation into clinical practice. The inclusion of investors and strategic partners will also bring a vital perspective on funding models, commercialization pathways, and the acceleration of cutting-edge therapies. Together, these voices will offer a comprehensive view of the trends transforming personalized healthcare on a global scale.

Networking Opportunities

Our precision medicine event, hosting over 500 attendees, offers invaluable networking opportunities. Bringing together professionals, researchers, and industry leaders, the event facilitates engaging discussions, knowledge-sharing, and potential partnerships, driving advancements in precision medicine.

Why Exhibit

Exhibiting at the event provides a unique opportunity to showcase your cutting-edge solutions and connect with key stakeholders in the rapidly advancing field of personalized healthcare. As an exhibitor, you’ll gain visibility among industry leaders, researchers, and professionals, allowing you to forge strategic partnerships, highlight your contributions to precision medicine, and stay at the forefront of innovations shaping the future of healthcare. Don’t miss the chance to position your company as a leader in this dynamic and transformative space, driving meaningful collaborations and contributing to the advancement of precision medicine.

THE LOCATION

APM Annual Conference 2025

Pennsylvania Convention Center
1101 Arch Street
Philadelphia, PA 19107

Philadelphia

Registration Fees

Student – free
Academic/Government/Non-Profit  – free
Healthcare Providers – free 
Investors – free
Vendor/Technology Provider $999

Other Live Conference Proceedings can be found on this Online Open Access Journal at:

Press Coverage

including a list of previous conference at:

Part Two: List of BioTech Conferences 2013 to Present

including Live Coverage of the 2024 Advancing Precision Medicine conference at:

Real Time Coverage Advancing Precision Medicine Annual Conference, Philadelphia PA November 1,2 2024

 

Read Full Post »

Sleeping Threats: Immune System’s Watch on Dormant Cancer

Posted in Adaptive Immune Response to Biomaterials and Tissue Repair, Anticancer Resistance, Artificial Intelligence - General, Artificial Intelligence in CANCER, Breast Cancer - impalpable breast lesions, Cancer - General, Cancer and Current Therapeutics, CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Genomics, cancer metabolism, Cancer Prevention: Research & Programs, Cancer Screening, cancer-general, Cancer-Immune Interactions, Funding Opportunities for Cancer Research, Human Immune System in Health and in Disease, Immune Engineering, Immunodiagnostics, Immunology, Immunotherapy, Innovation in Immunology Diagnostics, interventional oncology, Microbiome and Responses to Cancer Therapy, Modulating Macrophages in Cancer Immunotherapy, NK Cell-Based Cancer Immunotherapy, Population Health Management, Genetics & Pharmaceutical, Precision Cancer Medicine, Protection Against Autoimmune Disease, RNA Biology, Cancer and Therapeutics, Synthetic Immunology: Hacking Immune Cells, Uncategorized, tagged , , , , on June 6, 2025| Leave a Comment »

Sleeping Threats: Immune System’s Watch on Dormant Cancer

Curator: Dr. Sudipta Saha, Ph. D.

 

The immune system’s role in regulating dormant cancer cells has been increasingly elucidated, revealing a complex interplay that influences metastasis and cancer recurrence. Dormant cells, which enter a non-proliferative state, can evade immune detection and remain quiescent for prolonged periods.


Mechanisms of immune evasion include down-regulation of antigen presentation and residence within immune-privileged niches such as bone marrow. Both innate and adaptive immunity, particularly CD8+ T cells and natural killer cells, are involved in maintaining dormancy and preventing metastatic outgrowth.


Micro-environmental factors that modulate immune surveillance and dormancy status have been identified. Changes in cytokine profiles and inflammation can disrupt dormancy, leading to cancer cell reactivation and metastasis.


Therapeutic approaches to sustain dormancy or eliminate dormant cells are under development. These include immune checkpoint inhibitors, cancer vaccines, and cytokine modulators aimed at enhancing immune recognition and clearance.


By targeting dormant cancer cells through immune modulation, it is anticipated that metastasis can be delayed or prevented, significantly improving long-term patient outcomes and reducing cancer mortality.

References:

https://www.cancer.gov/news-events/cancer-currents-blog/2025/metastasis-dormant-cancer-cells-immune-system

https://www.nature.com/articles/nrc2256

https://pubmed.ncbi.nlm.nih.gov/33681821/

https://pubmed.ncbi.nlm.nih.gov/33811127/

https://www.nature.com/articles/nrc3910

https://pubmed.ncbi.nlm.nih.gov/27015306

 

Read Full Post »

Cancer Surgery Rethought: Immunotherapy Takes the Lead

Posted in Cancer - General, Cancer and Current Therapeutics, CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Informatics, Cancer Prevention: Research & Programs, Cancer Screening, Cancer Vaccines: Targeting Cancer Genes for Immunotherapy, cancer-general, Diagnostic Immunology, Immuno-Oncology & Genomics, Immunodiagnostics, Immunology, Immunotherapy, Metabolic Immuno-Oncology, Modulating Macrophages in Cancer Immunotherapy, Monoclonal Immunotherapy, Patient-centered Medicine, Personalized and Precision Medicine & Genomic Research, Population Health Management, Genetics & Pharmaceutical, Precision Cancer Medicine, tagged , , , , on May 2, 2025| Leave a Comment »

Cancer Surgery Rethought: Immunotherapy Takes the Lead

Curator: Dr. Sudipta Saha, Ph.D.

In a recent phase 2 study published in The New England Journal of Medicine, the efficacy of nonoperative management was assessed in patients with mismatch repair–deficient (dMMR) solid tumors. Instead of undergoing curative-intent surgery, patients with stage I to III dMMR tumors were administered immune checkpoint inhibitors.

The study was conducted across two cohorts involving 117 patients. After two years of follow-up, a recurrence-free survival rate of 92% (95% CI, 86 to 99) was achieved. It was found that complete clinical responses could be maintained without surgical intervention, and substantial preservation of organ function was observed.

The avoidance of surgery was associated with fewer treatment-related complications and a significant improvement in patients’ quality of life. It has been emphasized that dMMR tumors, being highly immunogenic, respond exceptionally well to immune checkpoint blockade, thereby offering a viable alternative to conventional surgery-based treatment plans.

While the study’s findings have been considered ground breaking, long-term data have been recommended to fully validate this approach. Future studies are expected to refine patient selection criteria and monitoring strategies to ensure sustained outcomes.

Overall, a potential shift in the standard of care for patients with early-stage dMMR tumors has been proposed, highlighting how personalized immunotherapy can redefine oncological practice.

References

https://www.nejm.org/doi/full/10.1056/NEJMoa2404512

https://pubmed.ncbi.nlm.nih.gov/28734759

https://pubmed.ncbi.nlm.nih.gov/26028255

https://www.mdpi.com/2072-6694/12/9/2679

https://pharmaceuticalintelligence.com/2024/09/16/immunotherapy-with-pembrolizumab-boosts-post-surgical-outcomes-in-high-risk-bladder-cancer-patients/
https://pharmaceuticalintelligence.com/2024/09/10/armored-cd7-car-t-cells-a-fratricide-resistant-solution-for-t-all-therapy/

Read Full Post »

Shaping the Future: The Rise of Structural Nanomedicine

Posted in Cancer and Current Therapeutics, Efficacy of Anti-Tumor T Cells, Nanotechnology for Drug Delivery, Patient-centered Medicine, Personalized and Precision Medicine & Genomic Research, Personalized Medicine Coalition, Population Health Management, Genetics & Pharmaceutical, Precision Cancer Medicine, tagged , , , , on May 2, 2025| Leave a Comment »

Shaping the Future: The Rise of Structural Nanomedicine

Curator: Dr. Sudipta Saha, Ph.D.

In their 2025 review, Mirkin, Mrksich, and Artzi describe how the field of structural nanomedicine is being transformed to revolutionize biomedical science. Therapeutic materials are now being designed with precise nanoscale architectures to optimize biological interactions, improve efficacy, and reduce side effects.

It is explained that, unlike traditional drug delivery methods, structural nanomedicine is centered on the engineering of form and function at the molecular level. Advances in DNA and RNA nanotechnology, self-assembling peptide systems, and engineered nanoparticles have been utilized to create customizable platforms capable of navigating complex biological environments. These structures are being programmed to respond to specific physiological triggers, thereby enabling targeted delivery and controlled release.

A strong emphasis is placed on how rational design principles—borrowed from materials science, chemistry, and bioengineering—are driving innovation. Examples are presented where precisely constructed nanostructures have been shown to outperform conventional therapies in cancer treatment, immunomodulation, and regenerative medicine.

Attention is drawn to the challenges that must still be addressed, including the scalability of manufacturing, regulatory barriers, and the need for deeper insights into nano-bio interactions at the systems level. It is argued that interdisciplinary collaboration will be required for the successful translation of structural nanomedicine from laboratory research to clinical application.

Ultimately, structural nanomedicine is portrayed as a paradigm shift—where passive carrier systems are being replaced by dynamic, functional architectures that actively engage in therapeutic processes. Optimism is expressed that through continued technological convergence, a new generation of precision therapies tailored to individual patients will be realized.

This review is recommended for researchers, clinicians, and industry professionals seeking to remain informed about future directions in biomedical innovation.

References

https://www.nature.com/articles/s44222-025-00306-5

https://www.nature.com/articles/s41551-019-0351-1

https://www.nature.com/articles/382607a0

https://pubs.acs.org/doi/10.1021/acsnano.3c06564

https://www.nature.com/articles/s41565-023-01447-7

https://pharmaceuticalintelligence.com/2015/10/10/nanotechnology-aptamers-for-specific-better-delivery-systems-of-existing-drugs/
https://pharmaceuticalintelligence.com/2016/02/29/nanoparticle-delivery-to-cancer-drug-targets/

Read Full Post »

Resitu Medical Sets Stage for Breakthrough in Breast Tumour Removal

Posted in Breast Cancer - impalpable breast lesions, Cancer - General, Cancer and Current Therapeutics, CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Informatics, cancer metabolism, Cancer Prevention: Research & Programs, Cancer Screening, cancer-general, Cancer-Immune Interactions, Circulating Tumor Cells (CTC), Immunodiagnostics, Immunotherapy, interventional oncology, Personalized and Precision Medicine & Genomic Research, Population Health Management, Genetics & Pharmaceutical, Precision Cancer Medicine, Surgical Procedure, tumor microenvironment, tagged , , , , on May 2, 2025| Leave a Comment »

Resitu Medical Sets Stage for Breakthrough in Breast Tumour Removal

Curator: Dr. Sudipta Saha, Ph.D.

Resitu Medical, a Swedish company specializing in minimally invasive breast tumour removal, has announced the appointment of Stefan Sowa as its new Chief Executive Officer. Strategic leadership is being strengthened as the company moves towards commercialization in both European and American markets.

A novel electrosurgical device, designed to excise entire breast lesions during the biopsy procedure, is being developed by Resitu. The device is intended to minimize the need for open surgery by allowing intact removal of tissue with minimal bleeding, guided by real-time ultrasound imaging. Preclinical studies are currently being conducted, and preparations for FDA clearance and CE marking are underway.

ISO 13485 certification for the design, development, manufacturing, and sales of the device has been successfully obtained. Investment has been secured from major shareholders, including Novoaim, ALMI Invest Stockholm, and STOAF, to support the finalization of the product and the initiation of serial production for clinical trials.

Through the use of its technology, false negatives are hoped to be reduced, while patient outcomes and diagnostic accuracy are expected to be significantly improved. The burden on healthcare systems may also be alleviated by minimizing the need for recalls and secondary biopsies.

Positive attention has been garnered at major medical conferences, with workshops hosted at events such as the Uppsala Breast Meeting, and favourable media coverage has been achieved. With Stefan Sowa at the helm, Resitu’s innovative device is poised to transform breast cancer management practices globally.

References

https://news.cision.com/let-em-know-ab/r/resitu-strengthens-c-suite-with-new-ceo-as-it-prepares-for-commercialization-of-its-breast-tumor-rem,c4140424

https://www.resitu.com

https://www.who.int/news-room/fact-sheets/detail/breast-cancer

https://pharmaceuticalintelligence.com/2019/02/13/tumor-ammonia-recycling-how-cancer-cells-use-glutamate-dehydrogenase-to-recycle-tumor-microenvironment-waste-products-for-biosynthesis/
https://pharmaceuticalintelligence.com/2016/04/10/lipids-link-to-breast-cancer/
https://pharmaceuticalintelligence.com/2016/03/14/rapid-regression-of-her2-breast-cancer/

Read Full Post »

Older Posts »